Immunotherapy for squamous esophageal cancer: a review
A Petrillo, EC Smyth - Journal of Personalized Medicine, 2022 - mdpi.com
Esophageal squamous cell carcinoma (ESCC) is a rare gastrointestinal tumour with high
mortality. A multimodality treatment based on chemoradiotherapy followed by surgery is the …
mortality. A multimodality treatment based on chemoradiotherapy followed by surgery is the …
The molecular characterization of genetic abnormalities in esophageal squamous cell carcinoma may foster the development of targeted therapies
U Testa, G Castelli, E Pelosi - Current Oncology, 2023 - mdpi.com
Esophageal cancer is among the most common tumors in the world and is associated with
poor outcomes, with a 5-year survival rate of about 10–20%. Two main histological subtypes …
poor outcomes, with a 5-year survival rate of about 10–20%. Two main histological subtypes …
Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
Y Qiao, C Zhao, X Li, J Zhao, Q Huang, Z Ding… - Frontiers in …, 2022 - frontiersin.org
Background Esophageal squamous cell carcinoma (ESCC) is the most common type of
esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of …
esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of …
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project …
DK Lee, SR Park, YH Kim, YG Lee, SJ Shin… - …, 2024 - Taylor & Francis
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed
cell death protein 1 (PD-1). We conducted a single-arm, phase 2 trial to investigate the …
cell death protein 1 (PD-1). We conducted a single-arm, phase 2 trial to investigate the …
Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous …
Q He, X Shi, J Yan, M Wu, C Gu… - … and clinical oncology, 2024 - spandidos-publications.com
Anti‑programmed cell death 1 immuno‑monotherapy has become the second‑line standard
treatment for advanced esophageal squamous cell carcinoma (ESCC) after the failure of first …
treatment for advanced esophageal squamous cell carcinoma (ESCC) after the failure of first …
Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal …
L Chao, J Liu, Y Chen, Y Fan, S Guo… - Thoracic Cancer, 2024 - Wiley Online Library
Background To evaluate the safety and efficacy of camrelizumab plus albumin paclitaxel
and carboplatin in the neoadjuvant treatment of borderline resectable or unresectable …
and carboplatin in the neoadjuvant treatment of borderline resectable or unresectable …